← All trials
NCT01659437
Phase 2/Phase 3Interventional
Trials that are a combination of phases 2 and 3.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 1, 2012
- Primary completion
- Jan 1, 2017
- Completion date
- Jan 1, 2018
- First posted
- —
- Last posted
- —
- Enrollment
- 415
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- University of GroningenLead sponsor
- University of GroningenOverall official - principal investigator
- World Health OrganizationStudy chair
- University of GroningenCollaborator
- Kwame Nkrumah University of Science and TechnologyCollaborator
- University of GhanaCollaborator
- World Alliance for Wound and Lymphoedema Care, SwitzerlandCollaborator
- National Buruli ulcer Control Programme, Ghana Health Service, Accra, GhanaCollaborator
- Kumasi Centre for Collaborative ResearchCollaborator
- University of GroningenReponsible party - principal investigator
- Drugs for Neglected Diseases InitiativeCollaborator
- Government of BeninCollaborator
- Kwame Nkrumah University of Science and TechnologyStudy director
- Noguchi Memorial Institute for Medical ResearchCollaborator
- University of AntwerpCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.